Mitigation of the somnolence of insulin-induced hypoglycemia by a vasopressin V1 receptor antagonist in the rhesus monkey

Ming Dao Chen, Tamas Ordog, Ernst Knobil

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Insulin-induced hypoglycemia causes somnolence in rhesus monkeys, a phenomenon usually considered an aspecific consequence of neuroglycopenia. Previous observations from our laboratory have raised the possibility that arginine vasopressin (AVP) may also play a role in this decrease in wakefulness. In the present study we tested this hypothesis by inducing hypoglycemia (~ 40 mg/dl) in ovariectomized rhesus monkeys by intravenous administration of insulin in the presence of continuous intracerebroventricular infusions of the V1 receptor antagonist [deamino- Pen1,O-Me-Tyr2,Arg8]-vasopressin (180 μg/60 μl per h) or of its vehicle alone (artificial cerebrospinal fluid, 60 μl/h). Wakefulness was assessed by a scoring system by observers blinded to the experimental protocol. The AVP antagonist significantly attenuated the decrease in wakefulness observed in response to insulin-induced hypoglycemia (p < .03) without increasing blood glucose levels. These and previous findings suggest that the somnolence induced by a moderate degree of hypoglycemia may not entirely be the direct consequence of neuroglycopenia and that AVP may, directly or indirectly, be involved.

Original languageEnglish (US)
Pages (from-to)497-503
Number of pages7
JournalPsychoneuroendocrinology
Volume23
Issue number5
DOIs
StatePublished - Jul 1998
Externally publishedYes

Fingerprint

Vasopressin Receptors
Macaca mulatta
Hypoglycemia
Arginine Vasopressin
Wakefulness
Insulin
Intraventricular Infusions
Vasopressins
Intravenous Administration
Cerebrospinal Fluid
Blood Glucose
Antidiuretic Hormone Receptor Antagonists

Keywords

  • Induced hypoglycemia
  • Insulin
  • Neuroglycopenia
  • Rhesus monkey
  • Somnolence
  • V receptor antagonist
  • Vasopressin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Endocrine and Autonomic Systems
  • Psychology(all)

Cite this

Mitigation of the somnolence of insulin-induced hypoglycemia by a vasopressin V1 receptor antagonist in the rhesus monkey. / Chen, Ming Dao; Ordog, Tamas; Knobil, Ernst.

In: Psychoneuroendocrinology, Vol. 23, No. 5, 07.1998, p. 497-503.

Research output: Contribution to journalArticle

@article{6201432736114684b01d3cbc42f889e0,
title = "Mitigation of the somnolence of insulin-induced hypoglycemia by a vasopressin V1 receptor antagonist in the rhesus monkey",
abstract = "Insulin-induced hypoglycemia causes somnolence in rhesus monkeys, a phenomenon usually considered an aspecific consequence of neuroglycopenia. Previous observations from our laboratory have raised the possibility that arginine vasopressin (AVP) may also play a role in this decrease in wakefulness. In the present study we tested this hypothesis by inducing hypoglycemia (~ 40 mg/dl) in ovariectomized rhesus monkeys by intravenous administration of insulin in the presence of continuous intracerebroventricular infusions of the V1 receptor antagonist [deamino- Pen1,O-Me-Tyr2,Arg8]-vasopressin (180 μg/60 μl per h) or of its vehicle alone (artificial cerebrospinal fluid, 60 μl/h). Wakefulness was assessed by a scoring system by observers blinded to the experimental protocol. The AVP antagonist significantly attenuated the decrease in wakefulness observed in response to insulin-induced hypoglycemia (p < .03) without increasing blood glucose levels. These and previous findings suggest that the somnolence induced by a moderate degree of hypoglycemia may not entirely be the direct consequence of neuroglycopenia and that AVP may, directly or indirectly, be involved.",
keywords = "Induced hypoglycemia, Insulin, Neuroglycopenia, Rhesus monkey, Somnolence, V receptor antagonist, Vasopressin",
author = "Chen, {Ming Dao} and Tamas Ordog and Ernst Knobil",
year = "1998",
month = "7",
doi = "10.1016/S0306-4530(98)00018-3",
language = "English (US)",
volume = "23",
pages = "497--503",
journal = "Psychoneuroendocrinology",
issn = "0306-4530",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Mitigation of the somnolence of insulin-induced hypoglycemia by a vasopressin V1 receptor antagonist in the rhesus monkey

AU - Chen, Ming Dao

AU - Ordog, Tamas

AU - Knobil, Ernst

PY - 1998/7

Y1 - 1998/7

N2 - Insulin-induced hypoglycemia causes somnolence in rhesus monkeys, a phenomenon usually considered an aspecific consequence of neuroglycopenia. Previous observations from our laboratory have raised the possibility that arginine vasopressin (AVP) may also play a role in this decrease in wakefulness. In the present study we tested this hypothesis by inducing hypoglycemia (~ 40 mg/dl) in ovariectomized rhesus monkeys by intravenous administration of insulin in the presence of continuous intracerebroventricular infusions of the V1 receptor antagonist [deamino- Pen1,O-Me-Tyr2,Arg8]-vasopressin (180 μg/60 μl per h) or of its vehicle alone (artificial cerebrospinal fluid, 60 μl/h). Wakefulness was assessed by a scoring system by observers blinded to the experimental protocol. The AVP antagonist significantly attenuated the decrease in wakefulness observed in response to insulin-induced hypoglycemia (p < .03) without increasing blood glucose levels. These and previous findings suggest that the somnolence induced by a moderate degree of hypoglycemia may not entirely be the direct consequence of neuroglycopenia and that AVP may, directly or indirectly, be involved.

AB - Insulin-induced hypoglycemia causes somnolence in rhesus monkeys, a phenomenon usually considered an aspecific consequence of neuroglycopenia. Previous observations from our laboratory have raised the possibility that arginine vasopressin (AVP) may also play a role in this decrease in wakefulness. In the present study we tested this hypothesis by inducing hypoglycemia (~ 40 mg/dl) in ovariectomized rhesus monkeys by intravenous administration of insulin in the presence of continuous intracerebroventricular infusions of the V1 receptor antagonist [deamino- Pen1,O-Me-Tyr2,Arg8]-vasopressin (180 μg/60 μl per h) or of its vehicle alone (artificial cerebrospinal fluid, 60 μl/h). Wakefulness was assessed by a scoring system by observers blinded to the experimental protocol. The AVP antagonist significantly attenuated the decrease in wakefulness observed in response to insulin-induced hypoglycemia (p < .03) without increasing blood glucose levels. These and previous findings suggest that the somnolence induced by a moderate degree of hypoglycemia may not entirely be the direct consequence of neuroglycopenia and that AVP may, directly or indirectly, be involved.

KW - Induced hypoglycemia

KW - Insulin

KW - Neuroglycopenia

KW - Rhesus monkey

KW - Somnolence

KW - V receptor antagonist

KW - Vasopressin

UR - http://www.scopus.com/inward/record.url?scp=0344972933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344972933&partnerID=8YFLogxK

U2 - 10.1016/S0306-4530(98)00018-3

DO - 10.1016/S0306-4530(98)00018-3

M3 - Article

VL - 23

SP - 497

EP - 503

JO - Psychoneuroendocrinology

JF - Psychoneuroendocrinology

SN - 0306-4530

IS - 5

ER -